$-1.83
(Market cap
$263 Mln
Revenue (TTM)
$85 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-15 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
44.46
-
EV/EBITDA
-19.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
392,578,808
10 Years Aggregate
CFO
$-373.06 Mln
EBITDA
$-478.67 Mln
Net Profit
$-743.48 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Standard Biotools Inc (LAB)
| -49.3 | -16.2 | -38.7 | -49.3 | -37.0 | -38.0 | -23.4 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Standard Biotools Inc (LAB)
| -26.9 | -20.7 | 88.9 | -34.7 | 72.4 | -59.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Standard Biotools Inc (LAB)
|
0.6 | 262.6 | 84.6 | -87.4 | -116.9 | -18.1 | -- | 0.5 |
| 63.4 | 8,484.6 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.1 | |
| 14.6 | 9,638.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.7 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.3 | |
| 57.9 | 9,074.5 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 180.5 | 10,905.5 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 16.4 | |
| 100.6 | 6,525.3 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24 | 5.0 | |
| 90.1 | 5,420.5 | 1,579.2 | 145.6 | 14.3 | 8.9 | 37.2 | 3.2 | |
| 321.7 | 12,752.7 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.4 | 8.4 | |
| 178.4 | 10,222.2 | 785.1 | 41.5 | 9.9 | 2 | 251.6 | 4.8 |
Shareholding Pattern
View DetailsAbout Standard Biotools Inc (LAB)
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East,... Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts. Read more
-
President, CEO & Director
Dr. Michael Egholm Ph.D.
-
President, CEO & Director
Dr. Michael Egholm Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Standard Biotools Inc (LAB)
What is the current share price of Standard Biotools Inc (LAB) Today?
The share price of Standard Biotools Inc (LAB) is $0.65 (NYSE) and $0.65 (NASDAQ) as of 28-Aug-2026 10:37 EDT. Standard Biotools Inc (LAB) has given a return of -37.02% in the last 3 years.
What is the current PB & PE ratio of Standard Biotools Inc (LAB)?
Since, TTM earnings of Standard Biotools Inc (LAB) is negative, P/E ratio is not available.
The P/B ratio of Standard Biotools Inc (LAB) is 0.46 times as on 21-Aug-2026, a 88 discount to its peers’ median range of 3.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.58 |
1.16 |
2024 |
-4.72 |
1.39 |
2023 |
-2.36 |
-1.19 |
2022 |
-0.49 |
-1.14 |
2021 |
-5.07 |
3.18 |
What is the 52 Week High and Low of Standard Biotools Inc (LAB)?
The 52-week high and low of Standard Biotools Inc (LAB) are Rs 1.72 and Rs 0.63 as of 28-Aug-2026.
What is the market cap of Standard Biotools Inc (LAB)?
Standard Biotools Inc (LAB) has a market capitalisation of $ 263 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Standard Biotools Inc (LAB)?
Before investing in Standard Biotools Inc (LAB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.